Recombinant DNA Advisory Committee - 12/3-4/92 
Dr. Post suggested that the EC or any other body can consult any subgroup of the RAC 
and use any subgroup of the RAC as consultants, but that the RAC as an entity should 
not entertain foreign proposals. 
Dr. Thierry Velu from Brussels University commented on the European request. He 
informed the RAC of an existing European human gene transfer committee which has 
recently been constituted. The first meeting of this committee was held several months 
ago. At the meeting, the committee discussed the establishment of an advisory body that 
would be equivalent to the RAC. However, the recommendation was rejected by the 
committee members for several reasons. The committee agreed that any review body 
would be constituted with investigators who desire approval of their own human gene 
transfer protocols. Composition of the committee by such individuals would represent a 
clear conflict of interest. The committee decided that a set of guidelines should be 
established as the first step of this process, and that these guidelines should be 
equivalent to the Points to Consider. 
Mr. Barton stated that an attempt to establish a resolution on this issue at this point may 
unintentionally draw lines and send signals that the RAC is not ready to send. 
Dr. D. Miller said that a reply should be made that the RAC would like to assist the EC; 
however, subject to time limitations, the committee cannot review an unlimited number 
of protocols. He added that there is not enough information available to the RAC about 
this request to provide an adequate response at this time. 
Dr. Murray stated that Mr. Barton and Dr. Schaechter have completed their terms as 
members of the RAC. Dr. Murray expressed the RACs appreciation for their 
dedication and contributions to the committee and thanked them for their service. Dr. 
Murray stated that this is her last meeting as Chair of the RAC and thanked Dr. Wivel 
and the staff of the Office of Recombinant DNA Activities for their assistance and said 
that it was an honor to have served on the RAC. The members of the RAC commended 
Dr. Murray for her dedication and service while serving as both a member and as Chair 
of the RAC. Dr. Murray has executed her responsibilities in an exemplary manner and 
the committee is indebted to her. 
IX. ADDITION TO APPENDIX D OF THE NIH GUIDELINES REGARDING A HUMAN 
GENE THERAPY PROTOCOL ENTITLED: CYSTIC FIBROSIS GENE THERAPY 
USING AN ADENOVIRUS VECTOR: IN VIVO SAFETY AND EFFICACY IN NASAL 
EPITHELIUM /DR WELSH 
[572] 
Recombinant DNA Research, Volume 16 
